Latest
industry research report on: Global Hereditary Angioedema Market :
Industry Size, Share, Research, Reviews, Analysis, Strategies,
Demand, Growth, Segmentation, Parameters, Forecasts
The report entitled Global
Hereditary
Angioedema
Market: Size, Trends & Forecasts (2017-2021) provides a detailed
analysis of the global hereditary market with analysis of market size
by value, growth, segments, etc.
The report also includes a
detailed regional analysis of the US and Europe hereditary angioedema
market comprising of hereditary market by value, segments and growth.
Under competitive landscape different products in the global
hereditary angioedema market have been compared on basis of various
technical parameters.
Moreover,
the report also assesses the key opportunities in the market and
outlines the factors that are and will be driving the growth of the
industry. Growth of the overall global hereditary angioedema market
has also been forecasted for the years 2017-2021, taking into
consideration the previous growth patterns, the growth drivers and
the current and future trends.
Shire
Plc, iBio, Inc., Pharming Group NV and CSL Limited are some of the
key players operating in the global hereditary angioedema market
whose company profiling is done in the report. In this segment of the
report, business overview, financial overview and the business
strategies of the companies are provided.
Country
Coverage
- The US
- Europe
Company
Coverage
- Shire Plc
- iBio,Inc.
- Pharming Group NV
- CSL Limited
Executive
Summary
Angioedema
can be defined as a disorder in which there is a rapid inflammation
of the dermis, subcutaneous tissue, mucosa (cavities surrounding
internal organs) and sub mucosal tissues. Angioedema can further be
divided into acquired and hereditary angioedema. Acquired angioedema
is generally caused due to allergy. On the other hand, hereditary
angioedema is caused due to genetic mutation.
Hereditary
angioedema (HAE) is defined as a condition highlighted by frequent
incidences of severe swelling. It is a rarely inherited disorder. It
most commonly affects limbs, face, intestinal and respiratory tract
and causes severe swelling in these parts of the body. Low levels of
C1 inhibitor, a protein leads to the over activation of bradykinin.
Bradykinin is a chemical which is the prime cause the occurrence of
angioedema.
The
global hereditary angioedema market is projected to increase at a
healthy rate during the forecasted period (2017-2021). This growth is
expected on account of many growth drivers such as increased
diagnosis in the US and Europe, advantages of preventive therapy,
approval of Berinert for pediatric treatment, launch of Haegarda C1
inhibitor and some other major products in the pipeline.
However,
the market also faces certain challenges such as high prophylaxis
cost, side effects of Cinryze and long term prophylactic treatment.
Oral therapy for hereditary angioedema attacks and SHP643 monoclonal
antibody are some of the trends in the global hereditary angioedema
market.
About
us
MarketResearchReports.biz
is the most comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save
time and money for our clients. We are a one stop solution for all
your research needs, our main offerings are syndicated research
reports, custom research, subscription access and consulting
services. We serve all sizes and types of companies spanning across
various industries.
Contact
Mr.
Nachiket
State
Tower
90
Sate Street, Suite 700
Albany,
NY 12207
Tel:
+1-518-621-2074
No comments:
Post a Comment